Dyadic International, Inc

Dyadic International is a U.S.-based biotechnology platform company that develops microbial protein production systems for industrial, life sciences, food and nutrition, and bio-industrial applications. It has no approved products for sale today and instead monetizes its C1 and Dapibus platforms through research collaborations, government grants, sublicensing, and related development services.

24,9 %

−238,3 %

−11,6 %

2.68

— Dyadic International, Inc
	%
Protein production platforms	45% Core microbial expression systems used to produce commercial quantities of proteins and enzymes.
Research collaboration services	35% R&D services performed under collaboration agreements and government or commercial projects.
Sublicensing and technology transfer	15% License-related arrangements, upfront fees, milestones, and potential royalties from platform IP.
Applied biotech programs	5% Targeted development programs in food, nutrition, life sciences, and bio-industrial markets.

Dyadic sells primarily to collaboration partners, licensees, and research sponsors rather than end consumers...

Collaboration partnersprimary
Partners fund research and development work and may pursue future licenses or commercialization rights.
Licensees and sublicense counterpartiesprimary
Companies that pay for access to Dyadic's platform IP, technology transfer, or milestone-based rights.
Government and grant-funded sponsorssecondary
Public or quasi-public programs that fund research projects and platform development.
European customerssecondary
Non-U.S. customers that buy research services or collaboration access and diversify the revenue base geographically.
Contract research organizationssecondary
CROs are not customers in the usual sense but are critical service providers enabling Dyadic's research execution.

Dyadic is headquartered in Jupiter, Florida and operates in the United States with a satellite office and foreign...

•Headquartered in Jupiter, Florida, United States
•Operates a foreign subsidiary and satellite office in the Netherlands
•Revenue comes from U.S. and European customers
•European customers represented 26.8% of 9M 2025 revenue
•Cross-border operations increase FX, tax, and compliance complexity

Dyadic is shifting from a research-driven organization toward a more commercially focused biotechnology platform under...

Commercialize the C1 and Dapibus platformsmedium-term

The company has no approved products, so platform monetization is the main path to durable revenue.

Build applied biotech partnershipsshort-term

Partnerships can fund development, validate the platform, and create downstream licensing opportunities.

Maintain liquidity and access to capitalshort-term

The company expects continued operating losses and may need external financing to fund development.

Dyadic remains a pre-commercial biotechnology company, so its results depend on successful platform validation, partner...

high

Customer concentration

A small number of customers accounted for most revenue and receivables, so losing one could materially reduce sales and cash flow.

Scope: Three customers accounted for 67.4% of 9M 2025 revenue
Materiality: high

high

Dependence on CROs

Research execution is outsourced to a few contract research organizations, creating operational dependency and potential delays or cost overruns.

Scope: Two CROs accounted for 87.6% of research services purchased in 9M 2025
Materiality: high

high

Capital needs and dilution

The company expects continued operating losses and may need to raise external capital to fund R&D and commercialization.

Scope: Potential equity, debt, or collaboration financing
Materiality: high

high

Commercialization and regulatory risk

The platforms must gain market acceptance and, for some programs, regulatory clearance before meaningful product revenue can emerge.

Scope: Microbial protein platforms and vaccine-related programs
Materiality: high

medium

Intellectual property risk

Value depends on protecting proprietary platform technology and license rights from challenge or obsolescence.

Scope: C1 and Dapibus platforms
Materiality: medium

Revenue recognition under ASC 606

Can shift revenue between quarters and affect comparability

Contract assets and deferred revenue

Affects working capital and reported revenue timing

Research and development expense recognition

Drives operating loss volatility

Stock-based compensation

Can materially affect reported operating costs

Investment securities and cash equivalents

Affects liquidity disclosure and interest income

Dyadic International, Inc

Customer concentration

Dependence on CROs

Capital needs and dilution

Commercialization and regulatory risk

Intellectual property risk

DYADIC INTERNATIONAL INC

Dometic Group

DMC Global Inc.

MANNKIND CORP

AFLAC INC

D. Boral ARC Acquisition I Corp.